biostudies-literatureUnknown40(8)Stockler MR<h4>Purpose</h4>We previously reported that enzalutamide improved overall survival when added to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its effects on aspects of health-related quality of life (HRQL).<h4>Methods</h4>HRQL was assessed with the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire and QLM-PR25 at weeks 0, 4, 12, and then every 12 weeks until progression. Scores from week 4 to 156 were analyzed with repeated measures modeling to calculate group means and differences. Deterioration-free survival was from random assignment until the earliest of death, clinical progression, discontinuation of study treatment, or a worsening of 10 points or more from baseline in fatigue, physical function, cognitiJournal of clinical oncology : official journal of the American Society of Clinical Oncology837-846https://www.ebi.ac.uk/biostudies/studies/S-EPMC8906451biostudies-literatureHealth-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.PMC8906451Horvath LGChi KNSandhu SMcDermott RHague WEChowdhury SThomson ASweeney CJMarx GMTan THMartin AJReaume MNMcJannett MBegbie SDWilliams SGDavis IDCoskinas XWinter DGNorth SADhillon HMYip SFrydenberg MENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)Joshua AMTan AParulekar WRPook DWVera-Badillo FStockler MRMcCaffrey JZhang AYLawrence NJZielinski RRParnis FfalseHealth-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.<h4>Purpose</h4>We previously reported that enzalutamide improved overall survival when added to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its effects on aspects of health-related quality of life (HRQL).<h4>Methods</h4>HRQL was assessed with the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire and QLM-PR25 at weeks 0, 4, 12, and then every 12 weeks until progression. Scores from week 4 to 156 were analyzed with repeated measures modeling to calculate group means and differences. Deterioration-free survival was from random assignment until the earliest of death, clinical progression, discontinuation of study treatment, or a worsening of 10 points or more from baseline in fatigue, physical function, cogniti2022-01-01T00:00:00Z2022 Mar2025-04-04T11:27:08.477Z2024-11-08T20:27:47.559ZS-EPMC89064513492870810.1200/JCO.21.00941